Azenta (AZTA) stock plummeted 5.66% in pre-market trading on Wednesday following the release of its second-quarter financial results for fiscal year 2025. The life sciences company's earnings fell short of analyst expectations, despite reporting better-than-expected revenue.

For the quarter ended March 31, 2025, Azenta reported adjusted earnings per share (EPS) of $0.05, missing the analyst consensus estimate of $0.07 by 28.57%. This figure remained unchanged from the same period last year. However, the company's quarterly revenue came in at $143 million, surpassing the analyst consensus estimate of $140.91 million by 1.48%. Despite the revenue beat, this represents a 10.14% decrease compared to sales of $159.13 million in the same quarter last year.

The company's financial performance was mixed, with an operating loss of $16 million for the quarter. The adjusted EBITDA margin stood at 10%, while the gross margin improved to 45.9%, up 140 basis points year-over-year. Azenta reiterated its revenue guidance from continuing operations for the fiscal year 2025, maintaining a cautious outlook amid evolving market conditions. The market's negative reaction suggests investors were particularly concerned about the earnings miss and the year-over-year revenue decline, overshadowing the slight beat on top-line expectations.